Analyst firms · Stifel · EW
Stifel EW price target and rating history
Edwards Lifesciences Corporation (EW) · Health Care
Stifel rates Edwards Lifesciences Corporation (EW) Buy with a $90 price target, as of its latest action on Jan 30, 2025. It has published 4 rating actions on EW since July 2021, including 1 upgrade and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110.
- Current rating
- Buy
- Price target
- $90
- Median target, all firms
- $110
- Actions on EW
- 4
Stifel price target on EW
Every Stifel rating on EW
- Jan 30, 2025
- Dec 6, 2022
- Jan 27, 2022
- Jul 30, 2021
How other firms rate EW
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Robert W. Baird | Outperform | $116 | Nov 5, 2026 |
| Truist Securities | Buy | $113 | Nov 4, 2026 |
| Barclays | Overweight | $110 | Oct 7, 2026 |
| UBS | Buy | $110 | Jul 28, 2026 |
| Leerink Partners | Outperform | $101 | Jul 24, 2026 |
| Wolfe Research | Outperform | $92 | Apr 1, 2026 |
| TD Cowen | Buy | $97 | Jan 9, 2026 |
Questions about Stifel and EW
- What is Stifel's price target for EW?
- Stifel's latest stated price target for Edwards Lifesciences Corporation (EW) is $90, from its action on Jan 30, 2025.
- What is Stifel's rating on EW?
- Stifel rates EW Buy, a bullish rating, as of Jan 30, 2025.
- When did Stifel last change its view on EW?
- On Jan 30, 2025, Stifel upgrades to Buy from Hold, price target $75 to $90.
- How does Stifel's EW target compare with other analysts?
- Across 7 firms with a EW price target in the last 12 months, the median target is $110.
More EW rating histories
- Robert W. Baird3
- Truist Securities3
- UBS5
- Leerink Partners6
- Wolfe Research6
- Raymond James6
- Jefferies4
- Oppenheimer4
- Evercore ISI3
- Piper Sandler4
- BofA Securities4
- Morgan Stanley6
- Citigroup4
- Wells Fargo6
- Credit Suisse3
All Stifel ratingsEW news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.